Imlunestrant (Synonyms: LY-3484356)

Name: Imlunestrant
Brand: MedChemExpress
SKU: HY-145572
Rating: 4.5 (1 reviews)

Cat. No.: HY-145572 Purity: 99.96% ee.: 100.00%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Imlunestrant (LY-3484356) is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC).

For research use only. We do not sell to patients.

Imlunestrant Chemical Structure

CAS No. : 2408840-26-4

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
250 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Imlunestrant:

(S)-Imlunestrant tosylate In-stock
Imlunestrant tosylate In-stock

1 Publications Citing Use of MCE Imlunestrant

•JCI Insight. 2025 May 6:e188051. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Estrogen Receptor/ERR Isoform Specific Products:

View All Isoforms

Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
MCF7	IC₅₀	17 nM Compound: 16; LY3484356	Antiproliferative activity against human MCF7 cells harboring ERalpha Y537N mutant assessed as inhibition of cell growth incubated for 6 to 7 days by high content imaging assay Antiproliferative activity against human MCF7 cells harboring ERalpha Y537N mutant assessed as inhibition of cell growth incubated for 6 to 7 days by high content imaging assay	[PMID: 37377342]
MCF7	IC₅₀	3 nM Compound: 16; LY3484356	Antiproliferative activity against human MCF7 cells harboring wild type ERalpha assessed as inhibition of cell growth incubated for 6 to 7 days by high content imaging assay Antiproliferative activity against human MCF7 cells harboring wild type ERalpha assessed as inhibition of cell growth incubated for 6 to 7 days by high content imaging assay	[PMID: 37377342]

In Vitro

LY3484356 shows favorable pharmacokinetic (PK) properties, including antitumor activity in ESR1 mutants^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

524.51

Formula

C₂₉H₂₄F₄N₂O₃

CAS No.

2408840-26-4

Appearance

Solid

Color

Light yellow to yellow

SMILES

OC1=CC2=NC=C(C3=CC=C(C(F)(F)F)C=C3O[C@]4([H])C5=CC=C(C=C5)OCCN6CC(C6)CF)C4=C2C=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (190.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9065 mL	9.5327 mL	19.0654 mL
5 mM	0.3813 mL	1.9065 mL	3.8131 mL
10 mM	0.1907 mL	0.9533 mL	1.9065 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.96% ee.: 100.00%

Select Batch:

Data Sheet (272 KB) SDS (252 KB)

COA (247 KB) HNMR (532 KB) CNMR (653 KB) RP-HPLC (263 KB) NP-HPLC (244 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Komal L. Jhaveri, et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study. 2021 ASCO Annual Meeting I.

[2]. Cristina Hernando, et al. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. Int. J. Mol. Sci. 2021, 22(15), 7812.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9065 mL	9.5327 mL	19.0654 mL	47.6635 mL
	5 mM	0.3813 mL	1.9065 mL	3.8131 mL	9.5327 mL
	10 mM	0.1907 mL	0.9533 mL	1.9065 mL	4.7664 mL
	15 mM	0.1271 mL	0.6355 mL	1.2710 mL	3.1776 mL
	20 mM	0.0953 mL	0.4766 mL	0.9533 mL	2.3832 mL
	25 mM	0.0763 mL	0.3813 mL	0.7626 mL	1.9065 mL
	30 mM	0.0636 mL	0.3178 mL	0.6355 mL	1.5888 mL
	40 mM	0.0477 mL	0.2383 mL	0.4766 mL	1.1916 mL
	50 mM	0.0381 mL	0.1907 mL	0.3813 mL	0.9533 mL
	60 mM	0.0318 mL	0.1589 mL	0.3178 mL	0.7944 mL
	80 mM	0.0238 mL	0.1192 mL	0.2383 mL	0.5958 mL
	100 mM	0.0191 mL	0.0953 mL	0.1907 mL	0.4766 mL

Imlunestrant Related Classifications

Cancer

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Imlunestrant2408840-26-4LY-3484356LY3484356LY 3484356Estrogen Receptor/ERRSERDER+HER2breast cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Imlunestrant (Synonyms: LY-3484356)

Customer Review

Other Forms of Imlunestrant:

Imlunestrant Related Antibodies

1 Publications Citing Use of MCE Imlunestrant

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Estrogen Receptor/ERR Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Imlunestrant Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Imlunestrant Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report